Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recruiting Phase 1 Trials for Tegavivint (DB17109)

Also known as: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

IndicationStatusPhase
DBCOND0131475 (Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05755087Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell LymphomaTreatment